Plain-English translation of NCT06306196 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing Hecolin®, a vaccine designed to protect against hepatitis E virus infection. Researchers want to see how well the vaccine works and how safe it is when given to children as young as 2 years old and to adults, including those living with HIV. The vaccine is given as three shots spaced over 6 months.
Hepatitis E is a serious liver disease that can affect people worldwide, but there is limited information about how well this medication protects children compared to adults. This trial will help doctors understand the best way to use the vaccine across different age groups, including vulnerable populations like people with HIV.
You likely qualify if…
You likely don't qualify if…
You would receive either three vaccine shots or a combination of shots and placebo (dummy shots) given at baseline, 1 month, and 6 months. Between shots, you'll have follow-up visits where blood samples are taken to measure your immune response. The entire study lasts about 7 months. Some participants (depending on their age group) will receive the full three-dose schedule, while others may receive two doses plus one placebo injection.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
South Africa